Pfizer Inc. (PFE.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
As of 10:27AM CEST. Market open.
| Previous close | 26.11 |
| Open | 26.56 |
| Bid | 26.16 x 0 |
| Ask | 26.22 x 0 |
| Day's range | 26.10 - 26.25 |
| 52-week range | 23.53 - 37.50 |
| Volume | |
| Avg. volume | 56,177 |
| Market cap | 148.521B |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | 1.56 (5.97%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
ZacksModerna (MRNA) Submits Updated COVID-19 Jab to FDA for Review
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
ZacksPfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ZacksGSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.
© 2024 Yahoo. All rights reserved.